Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Medical Genetics Ghent, |
RCV001530398 | SCV001468319 | likely pathogenic | Cutis laxa; Generalized arterial tortuosity | 2021-01-05 | criteria provided, single submitter | clinical testing | Several lines of evidence support the pathogenicity of the LOX variants in the patients’ phenotype. Firstly, the mutation is located in the catalytic domain, absent in control databases and predicted deleterious by all in silico prediction algorithms including Polyphen2, SIFT, Provean and Mutation Taster. Secondly, Lysyl oxidase directly interacts with Fibulin-4 (EFEMP2), the protein deficient in ARCL1B, with similar clinical effects on the vasculature, skin (cutis laxa), skeleton and respiratory system (including diaphragmatic abnormalities). Thirdly, several LOX knockout mouse models (Lox-/-) have been generated that presented with a very similar clinical phenotype to that seen in our patients. Fourthly, the ultrastructural findings can be interpreted as showing a significant fault in elastogenesis; the microfibrillar scaffolding of the elastic fibre is forming but the actual assembly of elastin in its interstices is minimal, all of which is consistent with a lysyl oxidase anomaly 6. |